The Blood Connection Inc

“The organization makes its 990 available to the public upon request.”

“An electronic copy of the form 990 was provided to the finance committee for their review and approval. After the finance committee's review, all trustees received an electronic copy for their review prior to the return's filing.”

“Each board member and key employee is provided a copy of the conflict of interest policy and signs a statement annually to document the receipt of the policy, reading and understanding the policy, and disclosing any potential conflicts of interest through answering a related set of questions. At the beginning of each board meeting, members are asked to disclose any potential conflict of interest based on the agenda set for the meeting. If a potential conflict is identified, the board determines whether a conflict exists and follows the policy to handle it.”

“Compensation for the ceo is set by the personnel committee and approved by the board.”

“COMPENSATION FOR THE EXECUTIVE VP/COO, EXECUTIVE VP/CHIEF TECHNICAL OFFICER, and CFO IS SET BY THE PERSONNEL COMMITTEE. COMPARABILITY DATA IS USED TO DETERMINE COMPENSATION AND INCLUDES REVIEW OF 990S FROM SIMILAR ORGANIZATIONS, REVIEW OF COMPENSATION DATA FOR SIMILAR POSITIONS FROM AN INDEPENDENT PARTY AND BLOOD CENTER INDUSTRY DATA, AND REVIEWS OF COMPENSATION PRACTICES BY INDEPENDENT CONSULTANT. COMPENSATION DECISIONS ARE DOCUMENTED IN COMMITTEE/BOARD MINUTES”

“The organization does not currently make its conflict of interest policy or governing documents available for public inspection. A summary of the organization's financial statements can be found on their website (http://thebloodconnection.org/about-us/).”

“Other Program Service Revenue - Total Revenue: 1062216, Related or Exempt Function Revenue: 1062216, Unrelated Business Revenue: , Revenue Excluded from Tax Under Sections 512, 513, or 514: ;”

“(Expenses $ 564,195 including grants of $)(Revenue $ 2,180,072) HEMATOPOIETIC PROGENITOR CELL PROCESSING SERVICES: PROVIDES CELLULAR THERAPY SERVICES INCLUDING PROCESSING, CRYOPRESERVATION, STORAGE, INFUSION PREPARATIONS FOR IMMUNOTHERAPY, AND TRANSPLANT FOR BOTH AUTOLOGOUS AND MATCHED RELATED TRANSPLANTS FOR MULTIPLE MYELOMA, NHL AND HODGKINIS LYMPHOMA. PROVIDES TRANSPLANT PRODUCT PREPARATION AND SHIPMENT PREPARATION TO AN OUTSIDE FACILITY UPON REQUEST. THE CRYOGENIC STORAGE SERVICES ARE PROVIDED FREE OF CHARGE FOR THE FIRST YEAR. GOALS: PROCESS 100% OF REQUESTS FOR PROCESSING AND INFUSIONS OF HEMATOPOIETIC PROGENITOR CELLS AND DONOR LYMPHOCYTES, OFFER SERVICES 24/7, PROVIDE SAME DAY TURNAROUND FOR CD34+ FLOW CYTOMETRY ANALYSIS, AND PRODUCE A PRODUCT PROVEN TO BE CAPABLE OF ENGRAFTMENT. CELLULAR THERAPY COLLECTION SERVICES: PROVIDES CELLULAR COLLECTION SERVICES FOR TWO HEALTHCARE PROVIDERS. ONE, A BIOTECHNOLOGY COMPANY (DENDREON) APPLIES ITS EXPERTISE IN ANTIGEN IDENTIFICATION, ENGINEERING AND CELL PROCESSING TO PRODUCE AN ACTIVE CELLULAR IMMUNOTHERAPY PRODUCT CALLED PROVENGE (SIPULEUCEL-T). PROVENGE IS INDICATED FOR TREATMENT OF ASYMPTOMATIC OR MINIMALLY SYMPTOMATIC METASTATIC CASTRATE RESISTANT PROSTATE CANCER. THE BLOOD CONNECTION COLLECTS MONONUCLEAR CELLS FROM PROSTATE CANCER PATIENTS DEEMED SUITABLE BY THEIR PHYSICIAN AND SCHEDULED BY DENDREON. POST COLLECTION, THE COLLECTED PRODUCT IS SHIPPED TO DENDREON FOR FURTHER TESTING AND PROCESSING; THE FINAL PRODUCT IS LATER TRANSFUSED BACK TO THE PATIENT AT THEIR TRANSFUSION CENTER. THE OTHER PROVIDER IS A CANCER TREATMENT INSTITUTE AFFILIATED WITH A LOCAL HOSPITAL SYSTEM. THE BLOOD CONNECTION COLLECTS CIRCULATING BONE MARROW CELLS FROM PATIENTS IN THE REMISSION PHASE OF CELLULAR CANCERS SUCH AS LEUKEMIA, LYMPHOMA, AND MYELOMA. THOSE COLLECTIONS, RICH IN HEMATOPOIETIC PROGENITOR CELLS, ARE THEN PROCESSED AS DESCRIBED ABOVE. ADDITIONAL PROGRAM EXPENSES INCLUDE INTEREST EXPENSES AND PROGRAM RELATED ADMINISTRATIVE EXPENSES.”

“This process has not changed from the prior year.”